TITLE

NEKTAR GETS $17.6 MILLION FROM AFFYMAX PACT FOR HEMATIDE

PUB. DATE
September 2006
SOURCE
Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on a payment received by Nektar Therapeutics under an undisclosed license agreement with Affymax Inc. for hematide. The deal has been triggered by Affymax's entry into a global agreement with Takeda Inc. to develop and commercialize its hematide lead product. Hematide is being tested for the treatment of anemia.
ACCESSION #
22045062

 

Related Articles

  • Deal watch: Nektar in US$1.5 billion licensing deal with AstraZeneca.  // Nature Reviews Drug Discovery;Nov2009, Vol. 8 Issue 11, p836 

    The article reports on the licensing deal of U.S.-based Nektar Therapeutics with AstraZeneca PLC for two compounds to combat opioid-induced constipation. The deal entails Nektar to receive an upfront payment of 125 million dollars and up to a total of 1.4 billion dollars in milestone payments....

  • Nektar in Technology Pact with Pfizer, Enzon.  // Chemical Market Reporter;8/9/2004, Vol. 266 Issue 5, p10 

    Reports on the separate agreements signed by Nektar Therapeutics with Enzon Pharmaceuticals Inc. and Pfizer Inc. Use of Enzon's proprietary polyethylene glycol (PEG) technology in the development of a Pfizer drug; Terms of the agreements; Number of pegylation technology collaboration between...

  • ZELOS/NEKTAR START PHASE 1 TRIAL OF INHALED OSTABOLIN-C.  // Worldwide Biotech;Nov2006, Vol. 18 Issue 11, p1 

    The article reports on a phase 1 clinical trial of an inhaled formulation of parathyroid hormone Ostabolin-C. Zelos Therapeutics Inc. collaborated with Nektar Therapeutics for the development of an inhaleable powder form of the drug in January 2005. Ostabolin-C is a bone formation agent used for...

  • CLINIC ROUNDUP.  // BioWorld Today;3/9/2010, Vol. 21 Issue 45, p7 

    This section offers clinical trial news briefs in the biotechnology industry as of March 9, 2010. Argos Therapeutics has reported positive results from a Phase II trial of AGS-003 in newly diagnosed patients with metastatic renal cell carcinoma. The enrollment of patients in a pivotal study of...

  • CLINIC ROUNDUP.  // BioWorld Today;1/14/2009, Vol. 20 Issue 8, p8 

    This section offers news briefs on clinical trials. AcelRx Pharmaceuticals Inc. reported positive results from a Phase I study evaluating the safety, tolerability and efficacy of the company's proprietary sublingual sufentanil and triazolam NanoTab combination product candidate (ARX-03). Aiko...

  • Nektar Halts Partnership Talks Over Exubera Cancer Concerns. Young, Donna // BioWorld Today;4/10/2008, Vol. 19 Issue 70, p1 

    The article reports on the decision of Nektar Therapeutics Inc. to stop partnership negotiations involving MannKind's Exubera after a new analysis of clinical trial data showed an increased risk of lung cancer. As a result, shares of Nektar declined by 25% or $1.80, to close at $5.39. Mannkind's...

  • Clinic Roundup.  // BioWorld Today;6/25/2010, Vol. 21 Issue 122, p3 

    This section offers news briefs on clinical trials in the U.S. biopharmaceutical sector as of June 25, 2010. Data reported by Access Pharmaceuticals Inc. showed increased reduction in pain and oral discomfort in patients taking MuGard drug. GlycoMimetics Inc. has initiated a Phase II trial of...

  • Nektar Therapeutics initiates Phase I acute pain study.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p13 

    The article reports on the initation of Nektar Therapeutics' Phase I clinical study on the pharmacokinetics and safety of NKTR-192, a mu-opioid analgesic candidate. It notes that the study discovers a decline in self-administration of NKTR-192 when it comes to forecasting the abuse liability of...

  • ECCO Meeting.  // BioWorld Today;9/28/2007, Vol. 18 Issue 189, p4 

    The article announces the findings of Nektar Therapeutics Inc. regarding preclinical results on NKTR-102 (PEG-irinotecan) in September 2007. Researchers say that an irinotecan-resistant mouse xenograft model showed remarkable dose-related suppression of tumor growth. The drug is in its Phase I...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics